12 results about "Cell Migration Inhibition" patented technology

The present disclosure provides methods for preventing, treating, or delaying progression of neuroinflammatory CNS conditions, e.g., Alzheimer's disease, by administration of an agent that inhibits macrophage migration inhibitory factor (MIF)-CD74 signaling. In some embodiments the agent to be administered is a MIF-binding protein such as a MIF antibody. In other embodiments disclosed herein the agent is a targeting polynucleotide against MIF or CD74.

The invention belongs to the technical field of biological pharmacy, and particularly relates to polylysine nanoparticles for delivering oxaliplatin and a preparation method of the polylysine nanoparticles. The invention discloses a preparation method of polylysine nanoparticles for delivering oxaliplatin. The polylysine nanoparticles are applied to preparation of a tumor targeting drug mPssPC-OXA NPs with small particle size, positive surface charge and excellent stability. The mPssPC-OXA NPs can respond to a tumor microenvironment with high GSH concentration to quickly release a drug, and shows an excellent HCT-116 cell uptake effect and an effective RAW264.7 cell immune escape effect in an in-vitro anti-colon cancer cell test. In addition, the mPssPC-OXA NPs also shows more remarkable cytotoxicity, cell migration inhibition, cell proliferation inhibition and HCT-116 cell apoptosis induction effects compared with free OXA.

The invention relates to application of a pinellia ternate exosome in preparation of a medicine for resisting non-small cell lung cancer, and belongs to the technical field of Chinese herbal medicines. According to the application of the pinellia ternate exosome in preparing the non-small cell lung cancer resisting medicine, the non-small cell lung cancer resisting medicine is a tumor cell proliferation inhibitor, a tumor cell migration inhibitor or a tumor cell apoptosis accelerant. The Pinellia ternate exosome PEs is dispersed with normal saline, the effective concentration is 10-100 g / mL, the Pinellia ternate exosome PEs retains various active components of Pinellia ternate, the growth and proliferation ability and healing ability of non-small cell lung cancer cells A549 can be significantly inhibited, apoptosis of the cells A549 can be promoted, growth of tumor tissues of tumor-bearing mice can be inhibited, and the Pinellia ternate exosome PEs can be used for treating tumor-bearing mice. The important application prospect is realized in the treatment of the non-small cell lung cancer.

Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and / or conditions with the compounds or the composition. The disease states and / or conditions are mediated through MIF / IgG or where MIF / IgG is a contributing factor to the development and perpetuation of diseases and / or conditions, such as autoimmune diseases and cancer, among others.

The invention provides a biomarker for diagnosing post-traumatic stress disorder and application of the biomarker, and belongs to the technical field of artificial intelligence medical treatment. The biomarker comprises at least one of matrix metallopeptidase 14, alpha1-antitrypsin, a macrophage migration inhibition factor, a tryptophan-tRNA ligase and a cell growth factor activator. The marker has high sensitivity and specificity in diagnosis of the post-traumatic stress disorder, can effectively diagnose the post-traumatic stress disorder in an early stage, provides a treatment target for subsequent treatment of the post-traumatic stress disorder, and has good clinical use and popularization and application values.

The invention discloses siRNA of a targeted AK4 gene and application of the siRNA, and belongs to the technical field of molecular biotechnology and genetic engineering. The invention discloses siRNA of a targeted AK4 gene. The sequences of the siRNA are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and / or SEQ ID NO.3, SEQ ID NO.4 and / or SEQ ID NO.5 and SEQ ID NO.6. The siRNA of the targeted AK4 gene provided by the invention can effectively inhibit cell proliferation and cloning, inhibit cell migration, promote cell apoptosis and promote improvement of cell sensitivity. The result shows that siRNA of the targeted AK4 gene can be used for preparing a cancer cell metastasis inhibitor and / or a medicine for treating cancers and a medicine for promoting improvement of cell sensitivity, promoting cell apoptosis, inhibiting cell migration and inhibiting cell proliferation and cloning. The invention provides a new technical means for developing new targets for tumor treatment, and has very important application value and prospect in clinical treatment of tumors and development of targeted drugs.

The present invention discloses a drug for treating nephritis, belonging to the field of biomedicine. The drug comprises a CX3CL1-CX3CR1 axis blocker. The drug can reduce monocyte migration; inhibit mesangial cell proliferation and activation; reduce CD45-positive cells in glomeruli; lower the mRNA expression levels of TNFα, IL-6, and IL-1β; and alleviate immune cell infiltration and inflammatory response in glomeruli. It can be used to treat mesangial proliferative glomerulonephritis.

The application discloses application of prolyl glycine in preparation of a medicine for treating and / or preventing endometriosis, wherein the prolyl glycine can inhibit proliferation of ectopic endometrial stromal cells, inhibit migration of ectopic endometrial stromal cells, inhibit development of a tissue structure of an endometriosis lesion, and reduce fibrosis of the endometriosis lesion, and the application provides a new biological basis and intervention idea for accurate typing and treatment of EMs.

This disclosure is based on a novel assay that links the degree of CXCR4 receptor occupancy (RO) by anti-CXCR4 polypeptides to the efficacy of anti-CXCR4 polypeptides, based on the determination of SDF-1α-induced migration of primary human CXCR4 cells in the presence of anti-CXCR4 polypeptides. Inhibition of migration, measured by the in vitro assay, provides a surrogate for the in vivo efficacy of anti-CXCR4 polypeptides.

The present invention relates to a fusion polypeptide derived from Toxoplasma gondii. The fusion polypeptide can be used as a pharmaceutical composition for treating tuberculosis. In particular, the fusion polypeptide according to the present invention acts specifically on the lungs infected with Mycobacterium tuberculosis and has therapeutic efficacy even against tuberculosis having resistance to isoniazid (INH), pyrazinamide (PZA), rifampin (RFP), and / or streptomycin (SM).

The application discloses one aspect of a kind of drug for treating atopic dermatitis in the preparation of targeting MIF application, another aspect discloses a kind of drug for treating atopic dermatitis.The drug for treating the atopic dermatitis is MIF small molecule inhibitor.The MIF small molecule inhibitor is MIF antagonist ISO-1.The application confirms that MIF has good therapeutic effect in HDM allergic mouse AD model by studying the therapeutic effect of phagocyte migration inhibitory factor MIF in HDM allergic mouse AD model.

The present invention relates to an inhibitor of EBV-infected B cell (EBV+ B cell) migration for use in treating and / or preventing an EBV associated disease in a subject, and to methods, kits, and uses related thereto.